November 15, 2007
Losses Augmented At Symbollon
By Matthew L. Brown
Symbollon Pharmaceuticals Inc. of Framingham reported a third quarter net loss of $667,441 on no revenue.
The company has reported no revenue since the first six months of 2006, when it brought in $40,000.
During the third quarter of 2006, the company reported a net loss of $663,043. For the nine months ended September 30, the company reported a net loss of $3.1 million. For the first nine months of 2006, Symbollon reported a net loss of $1.8 million. The company's losses are the result of increased clinical development expenses related to ongoing clinical trials of IoGen, the company's proprietary iodine-based treatment for pain associated with fibrocystic breast disease.
The company has reported no revenue since the first six months of 2006, when it brought in $40,000.
During the third quarter of 2006, the company reported a net loss of $663,043. For the nine months ended September 30, the company reported a net loss of $3.1 million. For the first nine months of 2006, Symbollon reported a net loss of $1.8 million. The company's losses are the result of increased clinical development expenses related to ongoing clinical trials of IoGen, the company's proprietary iodine-based treatment for pain associated with fibrocystic breast disease.
WBJ Web Partners
Most Recent
Most Recent
0 Comments